Triple-negative breast cancer: epidemiology and management options
1Department of Medical Oncology, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates. Shaheenah@post.harvard.edu
Abstract:
The triple receptor-negative breast cancer (TNBC) subtype is characterized by the lack of expression of both hormone receptors as well as lack of over-expression and/or lack of gene amplification of human epidermal growth factor receptor 2 (HER2). Approximately 10-15% of breast carcinomas are known to be of the TNBC subtype, which constitutes approximately 80% of all 'basal-like tumours'. Risk factors for TNBC include young age at breast cancer diagnosis, young age at menarche, high parity, lack of breast feeding, high body mass index and African American ethnicity. The majority of BRCA1 tumours are TNBC. TNBC has a worse prognosis and tends to relapse early compared with other subtypes of breast cancer. Conversely, it displays increased chemosensitivity compared with other breast tumour subtypes. Several agents are currently being investigated as potential therapeutic agents for the treatment of women with TNBC including agents targeted against EGFR, anti-angiogenic agents, multityrosine kinase inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors. This review focuses on the epidemiology of TNBC, its pathological features, natural history and recurrence patterns as well as current and future management options.
Insights
Triple receptor-negative breast cancer (TNBC) is an aggressive subtype with specific risk factors and early relapse patterns. Despite a worse prognosis, TNBC shows increased chemosensitivity, driving research into novel therapeutic agents.
Area of Science:
- Oncology
- Genetics
- Epidemiology
Background:
- Triple receptor-negative breast cancer (TNBC) lacks hormone receptors and HER2 overexpression, accounting for 10-15% of breast cancers and 80% of basal-like tumors.
- TNBC is associated with specific risk factors including young age, high parity, obesity, and African American ethnicity, with a majority of BRCA1-related cancers being TNBC.
- This subtype presents a poorer prognosis and earlier recurrence but demonstrates heightened chemosensitivity compared to other breast cancer types.
Purpose of the Study:
- To review the epidemiology, pathological characteristics, natural history, and recurrence patterns of TNBC.
- To explore current and emerging therapeutic strategies for TNBC management.
Main Methods:
- Literature review focusing on TNBC epidemiology, pathology, and clinical outcomes.
- Analysis of current and investigational treatment modalities for TNBC.
Main Results:
- TNBC exhibits distinct epidemiological and clinical features, including a propensity for early relapse.
- Increased chemosensitivity in TNBC suggests potential efficacy with specific chemotherapeutic agents.
- Ongoing research investigates targeted therapies such as EGFR inhibitors, anti-angiogenic agents, and PARP inhibitors.
Conclusions:
- TNBC is a distinct breast cancer subtype with unique challenges and therapeutic opportunities.
- Understanding TNBC's characteristics is crucial for developing effective treatment and management strategies.
- Targeted therapies hold promise for improving outcomes in patients with triple receptor-negative breast cancer.
Related Concept Videos
01:27Pulmonary Embolism III: Nursing Management
01:19Mitral Valve Prolapse III: Nursing Management
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:21Cancer Survival Analysis
02:17The Tumor Microenvironment
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...